Kalaris Therapeutics Inc (KLRS) USD0.0001

Sell:$4.47Buy:$4.90$0.12 (2.45%)

Prices delayed by at least 15 minutes
Sell:$4.47
Buy:$4.90
Change:$0.12 (2.45%)
Deal now
Prices delayed by at least 15 minutes
Sell:$4.47
Buy:$4.90
Change:$0.12 (2.45%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).

Key people

David L. Hallal
Executive Chairman of the Board
Andrew Oxtoby
Chief Executive Officer, Principal Executive Officer, Director
Brett R. Hagen
Chief Accounting Officer
Matthew Feinsod
Chief Medical Officer
Anthony P. Adamis
Director
Srinivas Akkaraju
Director
Michael Dybbs
Director
Napoleone Ferrara
Director
Morana Jovan-Embiricos
Independent Director
Click to see more

Key facts

  • Shares in issue
    18.70m
  • EPIC
    KLRS
  • ISIN
    US4829291065
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $88.46m
  • Employees
    6
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.